Clinical Context
A patient with homozygous familial hypercholesterolemia (HoFH) or severe refractory hypercholesterolemia attends a specialty infusion clinic for administration of a monoclonal antibody therapy, J1305 (evinacumab-dgnb, 5 mg). The typical patient is an adult or adolescent referred by a cardiologist, lipid specialist, or endocrinologist after inadequate response to maximally tolerated lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) and when LDL-C remains markedly elevated. Prior to the visit, baseline labs including lipid panel, liver function tests, and pregnancy testing (if applicable) are reviewed. The patient is screened for active infections and infusion contraindications.
On arrival, nursing performs an intake assessment, documents vitals and allergy history, and obtains informed consent for infusion. An intravenous catheter or appropriate peripheral access is prepared if the product is administered IV (based on product instructions). The infusion or injection is prepared by pharmacy per institutional protocol and administered by an RN or qualified infusion nurse. The patient is observed during and after the injection for immediate reactions; emergency medications and resuscitation equipment are available. Post-administration documentation includes lot number, NDC/HCPCS J1305 units administered, site of administration, and any patient response or adverse events.
Typical site of service: outpatient infusion clinic, specialty ambulatory infusion center, or hospital outpatient department. Service type: specialty drug injection/infusion therapy for lipid-lowering management in patients with severe familial or refractory hypercholesterolemia.